Author

Marie Luise Hütter‐Krönke

Observed names: Hütter-Krönke, Marie Luise, Hütter-Krönke, Marie-Luise, L-M Hütter-Krönke, M.-L. Huetter-Kroenke, M.-L. Hutter-Kronke, M.-L. Hütter-Krönke, M.L. Hütter-Krönke, Marie L. Hütter-Krönke, Marie Luise Huetter-Kroenke, Marie Luise Hutter-Kronke, Marie Luise Hütter-Krönke, Marie-Luise Huetter-Kroenke

Institutions: Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin

Observed institutions: Universität Ulm, Humboldt-Universität zu Berlin, University Hospital Ulm, Stiftung Charité, Freie Universität Berlin, Charité - Universitätsmedizin Berlin

ORCID: 0000-0002-4531-9889

Observed ORCID: 0000-0002-4531-9889

OpenAlex ID: A5019744121

PD-1 Blockade in Anaplastic Thyroid Carcinoma

2020 · Jaume Capdevila, Lori J. Wirth, et al. · Journal of Clinical Oncology · 353

PDF

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

2021 · Albiruni R. Abdul Razak, Sebastian Bauer, et al. · Clinical Cancer Research · 70

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

2025 · David J. Kuter, Waleed Ghanima, et al. · Blood · 58

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

2023 · Todd M Bauer, Armando Santoro, et al. · Journal for ImmunoTherapy of Cancer · 46

PDF

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis

2025 · Ioanna Minopoulou, Artur Wilhelm, et al. · Annals of the Rheumatic Diseases · 40

Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

2023 · Axel Matzdorff, Sonja R. Alesci, et al. · Oncology Research and Treatment · 29

PDF

Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

2021 · Todd Michael Bauer, Chia-Chi Lin, et al. · Journal of Clinical Oncology · 29

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy

2016 · M.-L. Hutter-Kronke, A. Benner, et al. · Haematologica · 24

Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis

2025 · Fredrik N Albach, Ioanna Minopoulou, et al. · Lara D. Veeken · 22

Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma

2018 · Albiruni Abdul Razak, Sebastian Bauer, et al. · Cancer Research · 15

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

2025 · Hartmut Döhner, Andre Schuh, et al. · Blood · 14

PDF

Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

2023 · Daniel Heudobler, Florian Luke, et al. · Haematologica · 12

PDF

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation

2023 · Marie Luise Hütter-Krönke, Adela Neagoie, et al. · Frontiers in Immunology · 12

PDF

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

2019 · Daniel Heudobler, Sebastian Klobuch, et al. · Blood · 11

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

2022 · Anne Sophie Kubasch, Aristoteles Giagounidis, et al. · Leukemia · 8

PDF

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series

2026 · Fredrik N Albach, Elpida Phithak, et al. · Annals of the Rheumatic Diseases · 7

Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome

2025 · Elpida Phithak, Fredrik N. Albach, et al. · Annals of the Rheumatic Diseases · 7

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

2025 · Jenny O'Nions, Andrew Wei, et al. · Blood · 5

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

2018 · Marie Luise Hütter-Krönke, Walter Fiedler, et al. · Haematologica · 5

PDF

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

2016 · S Bohl, S von Harsdorf, et al. · Bone Marrow Transplantation · 5

PDF

2025 · Andrew H. Wei, Jordi Esteve Reyner, et al. · Clinical Lymphoma Myeloma & Leukemia · 4

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

2024 · Waleed Ghanima, Howard A. Liebman, et al. · Blood · 4

PDF

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series

2026 · Elise Siegert, Elpida Phithak, et al. · Annals of the Rheumatic Diseases · 3

PDF

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

2024 · David J Kuter, Waleed Ghanima, et al. · Blood · 3

PDF

Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies

2026 · Ran Reshef, Jacques Azzi, et al. · Transplantation and Cellular Therapy · 2

Works count: 59

Citation count: 800

H-index: 12

I10-index: 14